Navigation Links
AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting

QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two posters on its PI3K inhibitor compound, AEZS-126, as well as a poster on its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, at the American Association for Cancer Research (AACR) Annual Meeting, to be held on April 18-22, 2009 at the Colorado Convention Center in Denver, Colorado.

    AEZS-126 (Poster #3705)

    - Entitled, "AEZS-126, a new orally bioavailable PI3K inhibitor with
      antitumor effects", I. Seipelt, S. Baasner, M. Gerlach, M. Teifel, J.
      Fensterle, L. Blumenstein, G. Mueller and E. Guenther, the poster
      focuses on ADMET and safety profiling of the compound, as well as in
      vivo pharmacokinetic experiments and mouse xenograft antitumor studies.

    AEZS-126 (Poster #3706)

    - Entitled, "In vitro profiling of the potent and selective PI3K
      inhibitor, AEZS-126", I. Seipelt, M. Gerlach, L. Blumenstein, G.
      Mueller, M.Teifel, E. Polymeropoulos and E. Guenther, the poster
      outlines the key in vitro characteristics of this compound that led to
      its selection for in vivo development.

    Both posters will be presented on Tuesday, April 21, 2009, between 8 a.m.
    and 12 p.m. (MT), during the Experimental and Molecular Therapeutics 23
    session in Hall B-F, Poster Section 35.

    AEZS-112 (Poster #5567)

    - Entitled, "Phase I dose-escalation, safety, and pharmacokinetic study
      of weekly oral AEZS-112, a small molecule anticancer agent in patients
      with advanced cancer and lymphoma", D. W. Northfelt, P. Griffin, H.
      Block, H. Sindermann, M. Teifel, D. Von Hoff, D. Mendelson, the poster
      outlines Phase 1 results for this orally-active tubulin and
      topoisomerase II inhibitor compound, in patients with advanced solid
      tumors and lymphoma, which may potentially provide a new therapeutic
      approach for the treatment of cancer.

    The poster will be presented on Wednesday, April 22, 2009, between 8 a.m.
and 12 p.m. (MT) during the Experimental and Molecular Therapeutics 42 session
in Hall B-F, Poster Section 37.

Copies of the abstracts that served for these posters are currently available and can be viewed on-line through the AACR 2009 Meeting website at:

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... The ... newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent ... the last few years. Many AMA members have embraced this type of racing and ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
Breaking Biology Technology:
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):